Age, sex, ECOG performance status, RAS mutational status, mismatch repair status, tumour sidedness (right vs. left colon vs. rectal cancer), prior exposure to anti-EGFR or anti-VEGF agents, and prior adjuvant therapy are all presented with hazard ratios (HRs) and 95% confidence intervals (CIs). This evidence concerns the gene EGFR and rectal cancer.